..., instructions or products referred to in the content or advertisements. 2023 Deferiprone Iron-chelation therapy Myelodysplastic syndromes Iron overload Oxidative stress Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal bone marrow (BM) stem cell malignancies characterized...

...). Patients remained on active treatment for a median time of 357 days (range, 154–557 days). Most of our patients had a performance status of ECOG 2 or higher. Three patients had myelodysplastic syndromes, 7 patients had acute myeloid leukemia, and 2 patients had myelofibrosis. The median number...

... between ESA and glucose in anemia-treated patients with myelodysplastic syndromes (MDS) or multiple myeloma (MM). Patients and Methods: Patients’ glucose levels were compared while on to while off ESA, and all served as their own controls. To test the association between ESA and blood glucose, we employed...

...Catharina Müller-Thomas; Heinz Tüchler; Martina Rudelius; Heike Schneider; Sabrina Pfefferkorn; Katharina S. Götze Background/Aims: There is growing evidence supporting the role of innate immune deregulation and inflammation in the pathogenesis of myelodysplastic syndromes (MDS). Vitamin D (VD...

...Na Wang; Fei Wang; Ningning Shan; Xiaohui Sui; Hongzhi Xu Background: Genomic sequencing technologies have identified isocitrate dehydrogenase ( IDH ) mutations in haematological malignancies. The prognostic implications of somatic IDH mutation ( mIDH ) in myelodysplastic syndromes (MDS) remain...

... deferasirox efficacy and safety in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other rare anemias. A 1-year, open-label, multicenter, single-arm, phase II trial was performed with deferasirox (10-40 mg/kg/day, based on transfusion frequency and therapeutic goals), including...

...Xingxin Li; Jun Shi; Min Wang; Neng Nie; Yingqi Shao; Meili Ge; Jinbo Huang; Zhendong Huang; Jing Zhang; Yizhou Zheng Clinical and experimental evidence suggests an immune-mediated pathophysiology in subjects with lower-risk myelodysplastic syndromes (MDS) in whom immunosuppressive therapy may...

... parameters and clinical outcomes. Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal, hematopoietic stem cell disorders characterized by improper differentiation and maturation of bone marrow cells, peripheral blood cytopenia, and an increased risk of developing acute myeloid leukemia...

... the results with those of myelodysplastic syndromes published in the literature, the prevalence of AID in these two groups of patients is similar. Our results also showed that the presence of cytogenetic abnormalities was less in CMML patients with AID (6 of 21; 28.6%) than in those without AID (37 of 94...

... tissue and glucose metabolism might be involved in the pathogenesis of myelodysplastic syndromes (MDS). Methods: Serum levels of cytokines related to the metabolism of bone tissue [osteocalcin and parathyroid hormone (PTH)], adipose tissue (adiponectin, leptin and ghrelin) and glucose [insulin...

...Bing Li; Zefeng Xu; Robert Peter Gale; Tiejun Qin; Yue Zhang; Zhijian Xiao Background: The International Prognostic Staging System (IPSS) for myelodysplastic syndromes (MDS) was developed predominately in patients of European ancestry and is not validated in Asians. In a recently revised IPSS (IPSS...

... ability to suppress anti-tumor immunity. This is particularly the case in myelodysplastic syndromes (MDS), which are clonal hematologic disorders characterized by marked immune dysregulation. We analyzed T reg frequencies in a cohort of 36 patients with early-stage MDS using a flow-cytometric approach...

... in 78 bone marrow samples from untreated patients with myelodysplastic syndrome (MDS) by PCR and Western blot analysis. Hypermethylation of DAPK1 was present in 42.3% (33 of 78) of MDS specimens and was significantly correlated with the loss of DAPK1 mRNA and protein expression (p < 0.01). There were...

...: To determine the frequency of Helicobacter pylori infection ( Hp -I) in 73 patients with myelodysplastic syndromes (MDS) and 40 controls, serologic analyses of Hp and 13 C-urease breath tests (INFAI) were performed. Gastric mucosal biopsy specimens were obtained to determine the presence of Hp -I using a rapid...

... in patients with various underlying anemias, including β-thalassemia, myelodysplastic syndromes, sickle cell disease, aplastic anemia, and other rare anemias. In addition to reducing key indicators of total body iron levels (serum ferritin, liver iron concentration, and toxic labile plasma iron), deferasirox...

...C. Sultan; M. Imbert; H. Jouault; J.Y. Scoazec The myelodysplastic syndromes (MDS) represent a group of syndromes having in common a defective production of one or more myeloid cell lines. They occur in patients which are more than 50 years old without any sex preponderance. The term MDS...

... therapy of myelodysplastic syndromes with excess of blasts. A critical review of the published data is presented. The preliminary results of a cooperative protocol using very low dosage of clytosine arabinoside (3 mg/m 2 /twice daily) with or without androgens are given 25 2 2009 © 1987 S...

...A. Inbal; E. Januszewicz; M. Rabinowictz; M. Shaklai The myelodysplastic syndromes are a group of bone marrow stem cell disorders which were considered refractory to chemotherapy until recently. Low-dose cytarabine was given to 6 patients with symptomatic myelodysplastic syndromes and 2 patients...

.... Myelodysplastic syndromes T lymphocyte subpopulations Original Papers Acta Haemat 1989;81:173-175 © 1989 S. Karger AG, Basel 0001 -5792/89/0814-0173 S 2.75/0 T Lymphocyte Subpopulations in Myelodysplastic Syndromes Giovanni Carpani, Alberto Rostí, Nadia Vozzo Laboratorio di Ematologia e Immunoematologia...

...R. Nano; R. Invernizzi; R. Rezzani; G. Gerzeli Dihydrofolate reductase (FH 2 -R) was studied cytochemically in the bone marrow erythroblasts of 20 normal controls and 46 patients with myelodysplastic syndromes (MDSs) classified according to FAB, prior to therapy. The reaction product was quantified...